Gilead v. Apotex: Consent Judgment in Tenofovir Alafenamide Patent Dispute

Case Overview

In a closely watched pharmaceutical patent infringement case, Gilead Sciences, Inc. secured a consent judgment against generic drug manufacturer Apotex, Inc. and Apotex Corp. in the U.S. District Court for the District of Delaware. Filed on July 14, 2023, and resolved on April 21, 2025, Case No. 1:23-cv-00775 centered on two foundational patents protecting tenofovir alafenamide hemifumarate — the active ingredient underlying Gilead’s antiviral drug franchise — and Apotex’s Abbreviated New Drug Application (ANDA) No. 218575 seeking generic market entry.

The resolution: a permanent injunction barring Apotex from manufacturing, selling, or importing the accused generic product in the United States, with all claims dismissed without prejudice and each party bearing its own costs.

For patent attorneys, in-house IP counsel, and pharmaceutical R&D teams, this case offers instructive lessons about ANDA litigation dynamics, consent judgment structuring, and strategic brand protection in the high-stakes small-molecule drug space.

The Parties

Patents at Issue

Two U.S. patents formed the basis of Gilead’s infringement claims, protecting tenofovir alafenamide hemifumarate, a prodrug form of tenofovir with improved renal and bone safety profiles:

• • U.S. Patent No. 8,754,065 — covers chemical compositions and formulations of tenofovir alafenamide
• • U.S. Patent No. 9,296,769 — covers related synthetic and pharmaceutical embodiments of the same compound

Apotex’s ANDA No. 218575 sought FDA approval for a generic version of a tenofovir alafenamide hemifumarate product, which triggered Gilead’s right to file suit under the Hatch-Waxman Act.

Litigation Timeline & Procedural History

The case was filed in the District of Delaware — the preeminent venue for Hatch-Waxman pharmaceutical patent litigation — and presided over by **Judge Maryellen Noreika**, a respected jurist with an extensive pharmaceutical patent docket.

The 647-day duration reflects a case trajectory consistent with negotiated resolution rather than full trial preparation. No publicly available record indicates significant contested motion practice, claim construction hearings, or summary judgment rulings prior to settlement. The parties appear to have moved toward resolution after assessing litigation risk, patent strength, and market timing considerations — a pattern common in ANDA litigation where the 30-month stay period under Hatch-Waxman shapes negotiating leverage on both sides.

The absence of a disclosed trial date or Markman hearing suggests settlement discussions commenced relatively early in the litigation lifecycle.

The Verdict & Legal Analysis

Outcome

On April 21, 2025, Judge Noreika entered a **Consent Judgment and Order** terminating the action. The key provisions included a **permanent injunction** barring Apotex, Inc. and Apotex Corp. from making, using, offering for sale, selling, or importing into the United States any product covered by ANDA No. 218575, unless authorized by Gilead or permitted under 35 U.S.C. § 271(e)(1). All affirmative defenses, claims, and counterclaims were dismissed **without prejudice**, preserving potential future litigation flexibility. No specific monetary damages were disclosed, consistent with most Hatch-Waxman consent judgments where the primary commercial remedy is market exclusion. Both parties waived all appellate rights, and each party bore its own costs. Notably, the order explicitly preserved the FDA’s authority to grant final approval to ANDA No. 218575, separating regulatory approval from commercial marketing rights.

Verdict Cause Analysis

This action was grounded in **patent infringement** under 35 U.S.C. § 271(e)(2) — the Hatch-Waxman infringement trigger for ANDA filings. Because the case resolved via consent judgment, no judicial findings on validity, infringement, or claim construction were made on the merits. The dismissal **without prejudice** of Apotex’s affirmative defenses — which would typically include invalidity, non-infringement, and potentially inequitable conduct — means those positions were never adjudicated. This is strategically significant: Apotex retains the theoretical ability to reassert defenses should it pursue a new ANDA or litigation pathway in the future.

Legal Significance

While consent judgments are not precedential on the merits, this resolution reinforces several important patterns in pharmaceutical patent litigation:

• • **Patent Holder Leverage in ANDA Litigation:** The 30-month stay and litigation costs create substantial pressure on generic filers to negotiate.
• • **Injunction Without Merits Ruling:** The permanent injunction achieved here — without any finding of infringement or validity — illustrates how Hatch-Waxman litigation can produce substantive IP protection through procedural settlement.
• • **Preservation of FDA Pathway:** Separating the regulatory approval pathway from commercial marketing rights is a sophisticated litigation tool allowing branded companies to maintain commercial exclusivity while avoiding blocking FDA processes.